CSF3 and Hodgkins lymphoma: Moreover, patients with DLBCL receiving CHOP regiments who are considered to have an intermediate neutropenia risk (10%‐20%) and no additional risk factors, such as age over 65 years, bone marrow involvement, renal/liver dysfunction, persistent neutropenia, recent surgery, and/or open wounds, do not require prophylactic use of granulocyte colony stimulating factor (G‐CSF) according to NCCN guidelines.7 In contrast to the DLBCL group, patients treated with HL receiving ABVD chemotherapy have an overall low neutropenia risk.